TargetMol

Tiragolumab (anti-TIGIT)

Product Code:
 
TAR-T35392
Product Group:
 
Primary Antibodies
Supplier:
 
TargetMol
Antibody Clonality:
 
Monoclonal
Regulatory Status:
 
RUO
Shipping:
 
cool pack
Storage:
 
-20℃
1 / 1
❮❯

No additional charges, what you see is what you pay! *

CodeSizePrice
TAR-T35392-1mg1mg£229.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T35392-5mg5mg£556.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
Prices exclude any Taxes / VAT
How to order with us   Contact us
Stay in control of your spending. These prices have no additional charges, not even shipping!
* Rare exceptions are clearly labelled (only 0.14% of items!).
Multibuy discounts available! Contact us to find what you can save.
This product comes from: United States.
Typical lead time: 10-14 working days.
Contact us for more accurate information.
  • Further Information
  • Documents
  • References
  • Show All

Further Information

Bioactivity:
Tiragolumab(MTIG-7192A) is a monoclonal antibody that targets T-cell immunoglobulin and the ITIM structural domain (TIGIT).Tiragolumab is often used in combination with the PD-L1 inhibitor, Atezolizumab, for the treatment of solid malignant tumors such as non-small cell lung cancer.
CAS:
0
Formula:
0
Molecular Weight:
0
Purity:
0.98
SMILES:
0

References

Houssaini MS, et al. Advances in the management of non-small cell lung cancer (NSCLC): A new practice changing data from asco 2020 annual meeting. Cancer Treat Res Commun. 2020;25:100239. Ge Z, et al. TIGIT, the Next Step Towards Successful Combination Immune Checkpoint Therapy in Cancer. Front Immunol. 2021 Jul 22;12:699895.